Valproic Acid
Diffuse Midline Glioma Histone 3 K27M WHO Grade IV
University of GöttingenSmall moleculePhase 3Dormant
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 95/ 100
Competitive context
8 Active assets in the Diffuse Midline Glioma Histone 3 K27M WHO Grade IV cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cetuximab University of Miami | Phase 1/2 | CCC |
CBL-0137 FREE BASE Children's Oncology Group | Phase 1/2 | CC |
h3k27m peptide vaccine German Cancer Research Center | Phase 1 | CC |
Imiquimod German Cancer Research Center | Phase 1 | CC |
Atezolizumab German Cancer Research Center | Phase 1 | CC |
VIPIVOTIDE TETRAXETAN Memorial Sloan Kettering Cancer Center | Phase 1 | CC |
Lorlatinib Nationwide Children's Hospital | Early Phase 1 | C |
azd1390 Children's Oncology Group | Phase 1 | NR |
Same molecule, other indications
Valproic Acid is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →